EXTON, Pa.--(BUSINESS WIRE)--Othera Pharmaceuticals, Inc. today announced that the first patient has been dosed in the OMEGA (OT-551 Multicenter Evaluation of Geographic Atrophy) trial, a planned 198 patient study of OT-551 eye drops as a treatment for geographic atrophy (GA), the advanced form of dry AMD. OT-551 could represent the first effective treatment for this chronic, degenerative disease which currently affects around one million elderly Americans.
